The IFNγ pathways shared the downstream IRF1 and STAT1 molecules that bound with the promoters of PD-L1 and CXCL10, enhancing the efficacy of anti-PD1/PD-L1 inhibitors and boosting T-cell infiltration in the tumor microenvironment [41]. Here, IRF1 is linked to neoplasm.